Evaxion Biotech A/S expected to post a loss of 21 cents a share - Earnings Preview

Evaxion A/S

04/08/2023 19:36

* Evaxion Biotech A/S  EVAX.OQ   EVAX.O  is expected to show
no
change in quarterly revenue when it reports  results on August 8
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Evaxion Biotech A/S
is
for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evaxion
Biotech
A/S is $10​, above​ its last closing price of $1.23. ​​​

This summary was machine generated August 4 at 18:36 GMT.  All
figures in US dollars  unless otherwise stated